Doloromics utilizes a human-first, multi-omic database of sensory tissue to identify and validate therapeutic targets for chronic diseases linked to neuro-immune dysregulation. This approach enhances the precision of drug development, aiming to deliver targeted relief through tailored medicines for specific patient needs.
Funding
$4.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MFFounders
Product
Problem
Current methods for discovering therapeutic targets for chronic diseases, particularly those linked to neuro-immune dysregulation, often lack the precision needed to develop effective treatments. Traditional drug development approaches may not adequately address the complex, patient-specific molecular mechanisms driving these conditions. This can lead to ineffective treatments and a lack of targeted relief for patients.
Solution
Doloromics is developing precision medicines for chronic diseases by utilizing a human-first, multi-omic database of sensory tissue. Their approach involves creating a high-fidelity molecular roadmap of disease condition-specific therapeutic targets through Neuro-immune Cartography. By starting with human disease tissues and multi-omically elucidating key drivers of neuro-immune dysregulation, Doloromics aims to validate relevant targets and design clinical candidates that modulate them. This enables the prospective design of a therapeutic pipeline addressing the root causes of diseases leading to imbalances in the neuro-immune axis, with the goal of delivering the right medicine for the right patient.
Target Audience
The primary target audience includes individuals suffering from chronic pain and other chronic diseases linked to neuro-immune dysregulation, as well as pharmaceutical companies seeking more precise and effective drug development strategies.
Features
- Multi-omic database of human sensory tissue for target discovery
- Neuro-immune Cartography platform for identifying disease condition-specific therapeutic targets
- Human-first approach using human disease tissues to elucidate key drivers of neuro-immune dysregulation
- Proprietary technologies to validate relevant targets and clinical candidates
- Therapeutic pipeline designed to address root causes of diseases leading to imbalances in the neuro-immune axis
- Utilizes single-cell RNA sequencing, proteomics, and epigenetic sequencing to understand molecular landscapes across disease